Global Stem Cell Therapies Competitive, Technological and R&D Landscape Report 2016 – Despite 330 Products in the Pipeline, Stem Cell Therapies Still Face Commercial Challenges – Research and Markets

DUBLIN, July 26, 2016 /PRNewswire/ —

Research and Markets has announced the addition of the “Stem Cell Therapies – Global Trends in the Competitive, Technological and R&D Landscape” report to their offering.

This report provides an assessment of the current trends in the global stem cell therapy sector, with a particular focus on the technological, competitive, and R&D landscape. It includes a targeted industry survey of experts and key opinion leaders in the stem cell therapies field, as well as extensive secondary research.

Stem cell therapies are one of the largest segments of the regenerative medicine market, even when non-therapeutic applications of stem cells are excluded.

This rapidly growing sector offers a number of opportunities to both biotechnology and pharmaceutical companies seeking to diversify away from traditional pharmacological compositions and towards a more therapeutic approach, similar to the successful arrival of targeted biologic therapies before the turn of the century. Stem cell therapy represents a very promising platform for clinical advancements in areas where current pharmacological and surgical treatment options are not effective.

These therapies have been in development for human therapeutic use for many decades and there has been steady progress in clinical research, with a few products having already entered the market. Moreover, information leveraged from our robust industry-leading database shows a diverse range of stem cell therapies currently in development for a wide range of indications, with some of these progressing to the later stages of clinical development.

Over 15 therapy areas are being targeted by the stem cell industry in over 1,000 clinical trials, our study shows. Our new report provides multilevel analysis of the R&D landscape including data split by therapy area, stage of development, company and many other insightful and pertinent analytics.

Converting the scientific potential of stem cell technology into real therapeutic value still represents a significant challenge, however. The stem cells field is still surrounded by a wide variety of scientific, technological, legal and ethical challenges, and suitability for commercial usage has been rather slow to attain. If stem cell therapies are to realize their full commercial potential manufacturers will need to adopt novel and comprehensive strategies to overcome these challenges, such as those described in this report.

Key Topics Covered:

1 Tables & Figures

2 Stem Cell Therapies Overview

3 Stem Cell Therapies: Key Marketed Products

4 Stem Cell Therapy Development: Drivers and Restraints

5 Stem Cell Production Strategies: Overview, Challenges and Recent Technological Advances 

6 Stem Cell Therapy Pipeline

7 Conclusion

8 Appendix

Companies Mentioned

– Chiesi Farmaceutici

– Medipost

– Mesoblast

– NuVasive

– Orthofix International

– Pharmicell

– Reliance Life Sciences

For more information visit

Media Contact:

Research and Markets

Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716


SOURCE Research and Markets

Leave a Reply

Your email address will not be published. Required fields are marked *